PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

The aim of the current study was to investigate the antitumor potential of poly (D,L-lactic-co-glycolic acid) microspheres (PLGA MSs) containing polyethylene glycol (PEG)-conjugated (PEGylated) tumor necrosis factor–related apoptosis-inducing ligand (PEG-TRAIL). PEG-TRAIL PLGA MSs were prepared by u...

Full description

Bibliographic Details
Main Authors:	Byeon, Hyeong Jun, Kim, Insoo, Choi, Ji Su, Lee, Eun Seong, Shin, Beom Soo, Youn, Yu Seok
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304599/

id	pubmed-4304599
recordtype	oai_dc
spelling	pubmed-43045992015-01-28 PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy Byeon, Hyeong Jun Kim, Insoo Choi, Ji Su Lee, Eun Seong Shin, Beom Soo Youn, Yu Seok Original Research The aim of the current study was to investigate the antitumor potential of poly (D,L-lactic-co-glycolic acid) microspheres (PLGA MSs) containing polyethylene glycol (PEG)-conjugated (PEGylated) tumor necrosis factor–related apoptosis-inducing ligand (PEG-TRAIL). PEG-TRAIL PLGA MSs were prepared by using a water-in-oil-in-water double-emulsion method, and the apoptotic activities of supernatants released from the PLGA MSs at days 1, 3, and 7 were examined. The antitumor effect caused by PEG-TRAIL PLGA MSs was evaluated in pancreatic Mia Paca-2 cell-xenografted mice. PEG-TRAIL PLGA MS was found to be spherical and 14.4±1.06 μm in size, and its encapsulation efficiency was significantly greater than that of TRAIL MS (85.7%±4.1% vs 43.3%±10.9%, respectively). The PLGA MS gradually released PEG-TRAIL for 14 days, and the released PEG-TRAIL was shown to have clear apoptotic activity in Mia Paca-2 cells, whereas TRAIL released after 1 day had a negligible activity. Finally, PEG-TRAIL PLGA MS displayed remarkably greater antitumor efficacy than blank or TRAIL PLGA MS in Mia Paca-2 cell-xenografted mice in terms of tumor volume and weight, apparently due to increased stability and well-retained apoptotic activity of PEG-TRAIL in PLGA MS. We believe that this PLGA MS system, combined with PEG-TRAIL, should be considered a promising candidate for treating pancreatic cancer. Dove Medical Press 2015-01-19 /pmc/articles/PMC4304599/ /pubmed/25632232 http://dx.doi.org/10.2147/IJN.S75821 Text en © Byeon et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Byeon, Hyeong Jun Kim, Insoo Choi, Ji Su Lee, Eun Seong Shin, Beom Soo Youn, Yu Seok
spellingShingle	Byeon, Hyeong Jun Kim, Insoo Choi, Ji Su Lee, Eun Seong Shin, Beom Soo Youn, Yu Seok PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
author_facet	Byeon, Hyeong Jun Kim, Insoo Choi, Ji Su Lee, Eun Seong Shin, Beom Soo Youn, Yu Seok
author_sort	Byeon, Hyeong Jun
title	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
title_short	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
title_full	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
title_fullStr	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
title_full_unstemmed	PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy
title_sort	pegylated apoptotic protein-loaded plga microspheres for cancer therapy
description	The aim of the current study was to investigate the antitumor potential of poly (D,L-lactic-co-glycolic acid) microspheres (PLGA MSs) containing polyethylene glycol (PEG)-conjugated (PEGylated) tumor necrosis factor–related apoptosis-inducing ligand (PEG-TRAIL). PEG-TRAIL PLGA MSs were prepared by using a water-in-oil-in-water double-emulsion method, and the apoptotic activities of supernatants released from the PLGA MSs at days 1, 3, and 7 were examined. The antitumor effect caused by PEG-TRAIL PLGA MSs was evaluated in pancreatic Mia Paca-2 cell-xenografted mice. PEG-TRAIL PLGA MS was found to be spherical and 14.4±1.06 μm in size, and its encapsulation efficiency was significantly greater than that of TRAIL MS (85.7%±4.1% vs 43.3%±10.9%, respectively). The PLGA MS gradually released PEG-TRAIL for 14 days, and the released PEG-TRAIL was shown to have clear apoptotic activity in Mia Paca-2 cells, whereas TRAIL released after 1 day had a negligible activity. Finally, PEG-TRAIL PLGA MS displayed remarkably greater antitumor efficacy than blank or TRAIL PLGA MS in Mia Paca-2 cell-xenografted mice in terms of tumor volume and weight, apparently due to increased stability and well-retained apoptotic activity of PEG-TRAIL in PLGA MS. We believe that this PLGA MS system, combined with PEG-TRAIL, should be considered a promising candidate for treating pancreatic cancer.
publisher	Dove Medical Press
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304599/
_version_	1613180247003365376

PEGylated apoptotic protein-loaded PLGA microspheres for cancer therapy

Similar Items